Creative Biogene Creative Biogene
Inquiry
Pages
Products
  1. Home
  2. Services
  3. Custom Viral Service
  4. Retrovirus Service
MMLV-Based Retrovirus Service
MSCV-based Retrovirus Service

Retrovirus Service

OverviewCROCDMOContact UsFAQ

Retroviral vectors are classic gene delivery tools widely used in cell engineering, gene therapy, and vaccine development. Their key advantage lies in stable integration into the host genome, supporting long-term expression, ideal for modifying dividing cells such as T cells, hematopoietic stem cells, tumor cells, and pluripotent stem cells. Although once eclipsed by next-generation vectors like lentiviruses, retroviral systems have regained momentum through improved promoters, envelope proteins, and packaging strategies, reaffirming their role in cell and gene therapy.

Building on advanced vector design and extensive manufacturing experience, Creative Biogene offers an integrated retroviral platform covering both CRO and CDMO services, meeting needs from research to clinical-grade production and accelerating therapeutic development.

Overview of the Retroviral System

The Retroviridae family is classified into seven genera: α-retrovirus, β-retrovirus, γ-retrovirus, δ-retrovirus, ε-retrovirus, lentivirus, and spumavirus. Among these, γ-retroviruses are currently the most widely used retroviral vectors in gene therapy and cell engineering. They are renowned for their stable genome integration, high-titer production, and mature biosafety profile, making them ideal for constructing long-term expression systems, T cell engineering, and stem cell modification.

Two classical vector systems form the foundation of our retroviral platform:

01

MMLV (Moloney Murine Leukemia Virus)

Widely used for generating stable cell lines, modifying T cells, and gene manipulation in dividing cells.

02

MSCV (Murine Stem Cell Virus)

Specifically optimized for pluripotent stem cells, offering resistance to epigenetic silencing and enabling long-term, high-level gene expression.

Both systems support pseudotyping with envelope proteins such as VSV-G, BaEV, and RD114, offering flexibility in tailoring viral tropism to various target cell types. Packaging strategies include both transient transfection systems and stable producer cell line platforms, making them suitable for workflows ranging from research-grade batches to scalable clinical production.

CRO Services: A Collaborative Platform for Research and Functional Verification

Creative Biogene's retroviral CRO services are designed to support key tasks during early-stage development, particularly in vector construction, functional testing, and expression stability assessment. Our expert team offers full technical support to help clients validate their targets and establish effective gene delivery systems.

CRO Service Portfolio

  • Vector Design & Construction
    • Construct expression vectors from GOI or RNA interference sequences.
    • Modular integration of promoters, reporter genes, and selection markers.
    • Use of MSCV enhancers optimized for stem cell-specific expression.
  • Envelope Selection & Targeting Recommendations
    • Multiple envelope options available: VSV-G, BaEV, RD114, Amphotropic Env.
    • Custom pseudotyping strategies based on specific cell types (T cells, HSCs, NK cells, etc.).
  • In Vitro Functional Verification
    • Titer determination via qPCR or infectious unit quantification.
    • Reporter expression analysis to assess transduction efficiency.
    • Long-term expression stability assays in dividing cells.
  • Custom Control Virus Generation
    • Matched EGFP or empty control viruses for use as internal assay references.
  • Analytical Method Development
    • Development and validation of assays for Replication-Competent Retrovirus (RCR) detection.
    • Establishment of methods for viral titer, endotoxin testing, and microbial load analysis.

CDMO Services: GMP Manufacturing Based on QbD Principles

As gene therapy products advance toward clinical and commercial applications, consistent processes, scalable output, and standardized quality control become crucial success factors. Creative Biogene has built a GMP-compliant CDMO platform for retroviral vectors based on Quality by Design (QbD) principles. This platform encompasses end-to-end services from process development and viral production to quality testing and regulatory submission support. Our CDMO capabilities support diverse production demands—from small-scale testing batches to IND-grade clinical virus lots—enabling smooth scale-up and regulatory readiness.

Process Development and Platform Capabilities

Service Highlights

Transfection & Virus Production Optimization

Supports HEK293T transient transfection and the development and transfer of stable producer cell lines (e.g., PG13).

Envelope Pseudotyping Flexibility

Compatible with VSV-G, BaEV, RD114, GALV, and other Env proteins for targeted delivery.

Seamless Scale-Up to GMP

Early-stage process development aligned with mid- and large-scale GMP production, minimizing scale-related variability.

Flexible Purification Strategies

Supports PEG precipitation, TFF ultrafiltration, and sucrose gradient ultracentrifugation, tailored by application needs.

Retroviral Vector CDMO Production Specifications

Grade Application Titer Yield Recommended Volume Purification Method Regulatory Documentation
Research Grade (RUO) Functional assays, model cell lines ≥10⁷ TU/ml ≥2×10⁸ TU 10–50 ml PEG concentration / crude prep Research-use report
Preclinical Grade Pharmacology/toxicology studies ≥10⁸ TU/ml ≥1×10⁹ TU 50–200 ml TFF + sucrose ultracentrifugation QC report, batch record, endotoxin data
GMP Grade IND/CTA submission, Phases I/II ≥10⁸ TU/ml (up to 10¹⁰ TU) ≥1×10¹⁰ TU Customized volume Multistep chromatography + final filtration COA, batch records, eCTD-ready documentation

Core Quality Control Capabilities

Quality control (QC) is central to the safe and effective use of retroviral vectors in both clinical and research settings. Our retrovirus platform features a comprehensive QC system aligned with international regulatory standards (FDA, EMA, WHO), covering critical quality attributes such as viral titer, safety testing, structural and functional validation, and method development. These controls ensure product consistency, biosafety, and regulatory readiness throughout vector development and manufacturing. We also support custom assay development to accommodate diverse payloads, target cell types, and retroviral constructs.

QC Module Test Item / Method Purpose / Regulatory Relevance
Viral Titer
  • qPCR for genomic titer
  • Infectivity assay (FACS, reporter-based, TCID50)
 Quantifies total and functional virus particles; supports lot release
Safety Testing
  • Sterility (USP<71>)
  • Mycoplasma (qPCR or culture)
  • Endotoxin (LAL,<5 EU/mL)
  • RCR detection
 Ensures absence of microbial or replication-competent contamination
Genetic & Functional Validation
  • Plasmid integrity (restriction mapping, sequencing)
  • GOI expression (qPCR, ELISA, Western blot)
  • Transduction efficiency (FACS, microscopy)
 Confirms genetic fidelity, expression functionality, and delivery efficiency
Impurity Analysis
  • Residual host cell DNA and proteins
  • Residual plasmid backbone
 Verifies the removal of process-related impurities
Method Development
  • Analytical method validation (ICH Q2(R1))
  • Stability testing (ICH Q1A(R2))
 Supports CMC documentation and product shelf-life studies

Regulatory Documentation Package

  • Batch Manufacturing Records (BMR)
  • Quality Control Summary
  • Method Validation Reports
  • Certificate of Analysis (COA)
  • Lyophilization process documentation
  • IND/CTA CMC module authoring (eCTD-compatible)

Partner with Creative Biogene

Creative Biogene is committed to enhancing viral vector quality and CMC process standardization. With years of technical accumulation and platform refinement, we have successfully supported multiple U.S. and EU regulatory submissions, offering turnkey solutions from research-grade development to GMP-compliant clinical production.

Our project teams are composed of experienced virologists, CMC scientists, and regulatory affairs experts—well-versed in IND readiness and regulatory response—ensuring your gene therapy projects progress efficiently from bench to bedside.

FAQ

Q: Can you accommodate custom payloads or large ORF inserts?

A: Yes. We routinely produce vectors carrying large or complex constructs, including multicistronic elements (IRES/2A) and gene-editing components (e.g., CRISPR, shRNA). Insert size limits depend on the packaging capacity (~8 kb for γ-retroviruses).

Q: Where is your manufacturing performed, and can you support European GMP compliance?

A: Our GMP facility is built to ISO 14644 standards and follows U.S. and EU GMP principles. We can provide GMP certificates, QC audit trails, and documentation aligned with EMA expectations.

Q: How do I choose between γ-retroviral and lentiviral vectors for my project?

A: The selection between γ-retroviral and lentiviral vectors depends on several key factors related to your target cells, expression needs, and application scenario. Below are general guidelines:

  • Target Cell Type: γ-retroviral vectors are ideal for dividing cells such as T cells or hematopoietic stem/progenitor cells (HSPCs), as they require cell division for genomic integration. For non-dividing cells like neurons or hepatocytes, lentiviral vectors are preferred due to their ability to transduce quiescent cells.
  • Stability of Gene Expression: If long-term, stable expression is required—such as in gene therapy or engineered cell lines—lentiviral vectors are more suitable. For short-term or transient expression, γ-retroviruses offer higher titers and faster production, making them a practical choice for screening or research use.
  • Immunogenicity Considerations: Lentiviral vectors generally induce a milder immune response and are therefore better suited for in vivo applications or immunologically sensitive models.
  • Payload Capacity: Lentiviruses support larger insert sizes (typically up to 8–10 kb), which is advantageous for delivering large genes or multicistronic constructs. γ-retroviral vectors have a more limited packaging capacity (typically ≤8 kb) and are less suited for oversized payloads.

If you're unsure which vector system aligns best with your project goals, our scientific team is available to provide tailored recommendations based on your target cell type, application strategy, and regulatory considerations.

Quick Inquiry
Products

Transfected Stable Cell Lines

Premade Virus Particles

Laboratory Equipment

RNA Interference Products

Cell Lysate

Clones

Enzymes

Kits

Aptamers

Services

Stable Cell Line Generation

Target-based Drug Discovery Service

Custom Libraries Construction Service

Microbe Genome Editing Service

Biosafety Testing Service

Nucleotides Service

MicroRNA Service

RNAi Service

Custom Viral Service

Platforms

CRISPR/Cas9 PlatformCB

QvirusTM Platform

IntegrateRNA Platform

Microbiology Platform

Zebrafish Platform

Get in Touch

Tel

Fax

Email

USA

Germany

Copyright © 2026 Creative Biogene. All rights reserved.

Privacy Policy | Cookie Policy